Highlights from Longevity Summit Dublin 2023
Key points and slides from the leading longevity conference hosted by Aubrey de Grey
Matt Kaeberlein
Professor at University of Washington and chair of the American Aging Association
Matt Kaeberlein, Ph.D., is recognized globally for his research on the basic biology of aging. The premise of his research is that understanding the molecular mechanisms of aging will lead to interventions that slow the onset and progression of age-related chronic conditions, such as cancer, diabetes, kidney disease, heart disease, Alzheimer’s and others. Dr. Kaeberlein received his Ph.D. from the Massachusetts Institute of Technology in 2002 and performed his post-doctoral research in the Department of Genome Sciences at the University of Washington. Dr. Kaeberlein was appointed as an Assistant Professor of Pathology in 2006 and was promoted to Associate Professor in 2011.
Dr. Matt Kaeberlein is a Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. His research interests are focused on basic mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published nearly 200 papers in top scientific journals and has been recognized by several prestigious awards, including a Breakthroughs in Gerontology Award, an Alzheimer’s Association Young Investigator Award, an Ellison Medical Foundation New Scholar in Aging Award, a Murdock Trust Award, a Pioneer in Aging Award, and the Vincent Cristofalo Rising Star in Aging Research.
Visit website: http://kaeberlein.org/matt-kaeberlein/
See also: 
University of Washington (UW)
- Public research university in Seattle, Washington
Details last updated 13-Feb-2020
Matt Kaeberlein is also referenced in the following:
Academy for Health and Lifespan Research (AHLR)
World's aging researchers unite to accelerate breakthroughs in longevity
American Aging Association
Non-profit dedicated to biomedical aging studies, geroscience and slowing the aging process
BSRA Annual Scientific Meeting 2023
06-Sep-2023 to 08-Sep-2023
A compelling lineup of speakers from all areas of the biology of ageing
Decoding Aging in Dogs (and Humans!)
25-May-2023
Decoding Longevity: Dogs, Humans, and the Shared Journey of Aging with Dr. Matt Kaeberlein by Oxford Society of Ageing and Longevity (FREE)
Dr. Matt Kaeberlein| Rapamycin, mTOR, Sirtuins, NAD+ & Dog Aging Project
Live Longer World podcast #5 with Dr. Matt Kaeberlein as a guest
Longevity Hackers
Feature length documentary about longevity and radical life extension with due to be released in 2023
Metabesity 2021
11-Oct-2021 to 14-Oct-2021
The Kitalys institute virtual conference targeting key questions that will impact the future of aging and extending healthspan
Rejuveron Age Better Live Longer Symposium
10-May-2022
Symposium about healthy living organized by Rejuveron (FREE)
Matt Kaeberlein Blog Posts
24-Aug-2023
Matt Kaeberlein News
Hunting for a new gold standard in longevity
Lifespan.io (LEAF) - 01-Nov-2024Ora biomedical’s high-tech screening could uncover life-extending compounds beyond rapamycin’s reach
Dr. Sajad Zalzala reports on PEARL rapamycin trial results
Live Forever Club - 28-Aug-2024Safety of rapamycin looks good and lean muscle mass among biomarkers trending towards improvement
Optispan investigates proactive healthcare to increase healthy lifespan
Longevity Technology - 01-Feb-2024Company aims to shift medicine's focus from illness treatment to proactive health optimization
New AI tool ENABL Age provides personalised insights into healthy ageing
Live Forever Club - 07-Nov-2023A stepping stone towards personalized anti-ageing interventions
Uncovering the potential of rapamycin from off-label use reports
Live Forever Club - 01-Jun-2023Friends and family noticed their improved health and appearance, with no serious side effects
Lifespan.io summarises the proceedings of the Buck Institute's Longevity Summit
Lifespan.io (LEAF) - 20-Jan-2023Another reminder of the amount of research, with multiple approaches, about to go into clinical trials
Phase 2 clinical trial of lead drug candidate MYMD-1- a therapy for delaying aging
Business Wire - 26-Jul-2022Sarcopenia drug trial shows no evidence of toxicity or safety issues
University of Washington launches Rapamycin Study
Live Forever Club - 05-Mar-2022Have you been taking rapamycin supplements recently? Please consider contributing to this study.
Building the future of longevity biotech: on deck fellowship expands with new cohort
Longevity Technology - 10-Dec-2021Mentorship and funding support for biotech innovators tackling ageing
First-ever true clinical trial to slow down ageing in dogs
Longevity Technology - 28-Sep-2021A rapamycin trial testing healthspan improvements in dogs; results may extrapolate to humans as well
Dr. Matt Kaeberlein argues for more funding for geroscience
The Hill - 16-Jul-2021Chair of American Aging Association disappointed ARPA-H may only receive half the requested funding
Recharge your mitochondrial batteries to live longer
Longevity Technology - 27-May-2021Breakthrough in longevity research - cellular energetics may stop or even reverse the ageing process
Dog Aging Project invites participants to study canine health and longevity
University of Washington - 13-Apr-2021Understanding the impact of genes, lifestyle, and environment on ageing
Stealthy Harvard startup wants to reverse aging
MIT Technology Review - 09-May-2018Rejuvenate Bio is cofounded by George Church of Harvard Medical School. Will make animals “young...
Life extending drug tested on dogs
Deccan Chronicle - 15-Aug-2016Anti-rejection drug rapamycin extend the life of mice by more than 25 per cent. If similar effec...
Articles written by Matt Kaeberlein
Dr. Matt Kaeberlein argues for more funding for geroscience
The Hill - 16-Jul-2021Chair of American Aging Association disappointed ARPA-H may only receive half the requested funding
